Strepsils Intensive tab for the races. 8.75mg 24 pieces of honey-lemon

Description

Composition
Active substance:
1 tablet contains: 8.75 mg of flurbiprofen
Excipients:
Macrogol 300 5.47 mg, 2.19 mg of potassium hydroxide, liquid sucrose 1407 mg, levomenthol 2 mg dextrose 1069 mg 50.4 mg honey lemon flavor (502904 A) 3.6 mg.
Description:
Round pellets of the translucent caramel mass from light yellow to light brown, with the image of the letter S from 2 sides of the tablet. Presence of air bubbles in the candy mass and a slight unevenness of the edges. Perhaps the appearance of white bloom.
Product form:
Lozenges [honey-lemon] 8.75 mg.
12 tablets in a blister (PVC / PVDC / Aluminum). 3 blisters were placed in a cardboard box, together with instructions for use.
Contraindications
Hypersensitivity to any component of the drug; peptic ulcer (exacerbation); asthma and rhinitis in patients receiving aspirin or other nonsteroidal antiinflammatory drugs; children’s age (12 years); deficiency of glucose-6-phosphate dehydrogenase, pregnancy, lactation.
Be wary of: hyperbilirubinemia (including Gilbert syndrome, Dubin-Dzhoisona and Rotor), chronic circulatory insufficiency, edema, hypertension, hemophilia, anticoagulation, gastric ulcer or duodenal ulcer (in remission, history), hepatic and / or renal failure, reducing blood clotting, inhibition of bone marrow hematopoiesis, hearing loss, vestibular pathology. In the appointment of the elderly, use of the drug is possible only after consultation with your doctor.
Dosage
8.75 mg
Indications
As means for the symptomatic relief of sore throat in infectious and inflammatory diseases of the mouth and pharynx.
Interaction with other drugs
Avoid the simultaneous application of flurbiprofen to the following drugs:
• Acetylsalicylic acid: with the exception of low-dose acetylsalicylic acid (not more than 75 mg per day), prescribed by the doctor, since the combined use may increase the risk of side effects.
• Other NSAIDs, including ibuprofen and selective cyclooxygenase-2 inhibitors: avoid simultaneous use of two or more drugs from the group of NSAIDs due to possible increased risk of side effects.
Precautions used simultaneously with the following drugs:
• Anticoagulants: NSAIDs may enhance the effect of anticoagulants, particularly warfarin.
• Antiplatelet agents and selective serotonin reuptake inhibitors: increased risk of gastrointestinal bleeding.
• Antihypertensive agents (ACE inhibitors and angiotensin II) and diuretics NSAIDs may reduce the effectiveness of drugs and these groups may increase the nephrotoxicity due to inhibition of cyclooxygenase, especially in patients with impaired renal function (need to provide adequate compensation fluid in these patients).
• Alcohol may increase the risk of adverse events, especially bleeding in the gastrointestinal tract.
• Cardiac glycosides: the simultaneous use of cardiac glycosides and NSAIDs can lead to aggravation of heart failure, decreased glomerular filtration rate and an increase in concentration of cardiac glycosides in blood plasma.
• Cyclosporin: increased risk of nephrotoxicity with concomitant use of NSAIDs and cyclosporin.
• Corticosteroids: increased risk of ulcers of the gastrointestinal tract and gastrointestinal bleeding.
• Lithium Drugs: There are data on the probability of increasing the concentration of lithium in blood plasma during treatment with NSAIDs.
• Methotrexate: there is evidence of the likelihood of increasing concentration of methotrexate in the blood plasma during treatment with NSAIDs. NSAIDs should be taken for 24 hours before or after taking methotrexate.
• Mifepristone: NSAIDs should not start earlier than
8-12 days after administration of mifepristone, as NSAIDs can reduce the effectiveness of mifepristone.
• Antibiotics of the quinolone series: patients receiving collaborative care NSAIDs and quinolone antibiotics series, may increase the risk of seizures.
• Tacrolimus: the simultaneous use of NSAIDs and tacrolimus may increase the risk of nephrotoxicity.
• Zidovudine: the simultaneous use of NSAIDs and zidovudine may increase gematotoksichnosti.
• Oral hypoglycemic agents: you can change the level of glucose in the blood (it is recommended to increase frequency of monitoring blood glucose levels).
• Phenytoin: may increase serum levels of phenytoin (recommended serum levels of phenytoin controls and, if necessary, dose adjustment).
• Potassium-sparing diuretics combined use of potassium-sparing diuretics and flurbiprofen can cause hyperkalemia.
• Probenecid and sulfinpyrazone: Medicinal products that contain probenecid or sulfinpyrazone may delay the excretion of flurbiprofen.
• Tolbutamide and antacids: to date, studies have not revealed the interactions between flurbiprofen and tolbutamide or antacids.
Overdose
Symptoms include nausea, vomiting, epigastric pain, or more rarely, diarrhea, tinnitus, headache and gastrointestinal bleeding. In more severe cases, there are manifestations of the central nervous system: drowsiness, rarely – excitement, convulsions, disorientation, coma. In cases of severe poisoning can develop metabolic acidosis and increased prothrombin time, acute renal failure, liver damage, blood pressure, respiratory depression and cyanosis. Patients with asthma may increase the disease.
Treatment: symptomatic, with obligatory airway, ECG monitoring and vital signs up to the normalization condition of the patient. We recommend the use of activated charcoal oral or gastric lavage for one hour after ingestion of potentially toxic dose of flurbiprofen. Frequent or prolonged convulsions should be to stop the intravenous administration of diazepam or lorazepam. When exacerbation of asthma recommend the use of bronchodilators. Specific antidote to flurbiprofen does not exist.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug (NSAID)
Pharmacodynamics:
The mechanism of action of flurbiprofen associated with inhibition of the enzymes cyclooxygenase 1 and cyclooxygenase 2 followed by inhibition of prostaglandin synthesis – mediators of pain. It has anti-inflammatory and analgesic effect. The drug has no effect protivomnkrobnym. Effect of the drug occurs within 30 minutes after the start of resorption tablet in the oral cavity, and continuing for 2-3 hours.
Pharmacokinetics:
Absorption – high. Communication with the plasma proteins up to 99%. Maximum plasma concentration (Cmax) is achieved after 30-40 min. Basically metaboliznruetsya through hydroxylated and excreted by the kidneys. Poluvyvsdsiiya period (T1 / 2) is 3-6 hours.
Pregnancy and breast-feeding
Do not use this drug in the III trimester. It should avoid the use of flurbiprofen in the I-II trimester of pregnancy should consult a physician if required using the drug.
There is evidence that the flurbiprofen in small quantities can penetrate into breast milk without any adverse effects on the infant’s health, however, because of the possible side effects of NSAIDs use of the drug is not recommended during breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
The risk of side effects can be minimized, if you take a short course of the drug in the lowest effective dose needed to control symptoms.
The following adverse reactions were observed in short-term use of the drug. In the treatment of chronic conditions and long-term use may cause other adverse reactions.
estimates of frequency of adverse reactions produced on the basis of the following criteria: very common (> 1/10), common (by> 1/100 to 1/1000 and 1/10 000
Blood disorders and lymphatic system • Frequency unknown: a violation of hematopoiesis (anemia, thrombocytopenia).
Disorders of the nervous system • Often: dizziness, headache, paresthesia.
• Uncommon: somnolence.
Violations by the immune system • Rare: anaphylactic reactions.
Violations of the heart • Frequency not known: heart failure, edema.
Violations by vessels • Frequency not known: high blood pressure.
Violations of the respiratory system, thorax and mediastinum • Common: feeling of irritation in the throat.
• Uncommon: asthma and bronchospasm, dyspnea, wheezing, blisters in the oral cavity and pharynx, pharyngeal hypoesthesia (reduced sensitivity in the oral cavity and pharynx).
Disorders of the gastrointestinal tract • Often: diarrhea, ulceration of the mouth, nausea, pain in the mouth, paraesthesia oral, pain in the mouth and throat, discomfort in the mouth (feeling of warmth, burning or tingling in the mouth).
• Uncommon: bloating, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossalgia (burning mouth syndrome), dysgeusia (taste perception change), dysesthesia oral vomiting.
Violations of the skin and subcutaneous tissue disorders • Uncommon: skin rash, itching.
• unknown frequency: severe skin reactions such as bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell’s syndrome).
Disorders of the liver and biliary tract Frequency • unknown: hepatitis.
mental disorders • Uncommon: insomnia.
Other • Uncommon: fever, sore.
special instructions
Diabetics should take into account that the tablet contains about 2.5 grams of sugar.
In the case of a combination of pain in the throat with a significant increase in body temperature, the drug can be recommended by a doctor.
If necessary, the definition of 17-ketosteroids drug should be discontinued 48 hours prior to the study. While maintaining high temperature, headache, or other adverse events should consult a doctor.
Do not exceed the dosage specified in the instructions.
Storage conditions
Store at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Adults and children over 12 years: Slowly dissolve 1 tablet every 3-6 hours. The maximum daily dose of 5 tablets.
Do not exceed this dose.
Duration of treatment – no more than 3 days. If you are taking the drug within 3 days, the symptoms persist, you must stop treatment and seek medical advice.
Please read the instructions before taking the drug.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist